N-hydroxyalkyl, hydroxyalkoxyalkyl and hydroxyalkoxyalkoxy-alkyl diphenyl-methylene-piperidines

ABSTRACT

New diphenyl-methylene-piperidines acting upon the cardiovascular, pulmonary and central nervous systems and as antihistaminics and antiserotoninics, having the general formula WHEREIN A is hydrogen, halogen, cyano, halomethyl, alkyl or alkoxy and R is hydroxyalkyl, hydroxyalkoxyalkyl or hydroxyalkoxyalkoxyalkyl; and the pharmaceutically acceptable addition salts thereof.

United States Patent Zivkovic [451 Aug. 29, 1972 541 N-HYDROXYALKYL,

HYDROXYALKOXYALKYL AND HYDROXYALKOXYALKOXY-ALKYL DIPHENYL-METHYLENE-PIPERIDINES [72] Inventor: Dusan Zivkovic, Rhode-Saint- Genese, Belgium [73] Assignee: UCB Societe Anonyme, saint Gillesv e rfi P illeaB vm [22] Filed: April 6, 1970 [21] Appl. No.: 26,164

[30] Foreign Application Priority Data April 9, 1969 Great Britain ..l8,229/69 [52] U.S. Cl. ...260/293.83, 260/293.84, 260/293.75, 260/293.72, 260/294.9, 260/297 R, 424/267 3,530,126 9/1970 Bemasconiet al.260/294.7M

FOREIGN PATENTS OR APPLICATIONS 548,012 10/1957 Canada ..260/294.7 M

Primary Examiner-Henry R. Jiles Assistant Examiner-S. D. Winters Att0rney-Wenderoth, Lind & Ponack [57] ABSTRACT New diphenyl-methylene-piperidines acting upon the cardiovascular, pulmonary and central nervous systems and as antihistaminics and antiserotoninics, having the general formula wherein A is hydrogen, halogen, cyano, halomethyl, alkyl or alkoxy and R is hydroxyalkyl, hydroxyalkoxyalkyl or hydroxyalkoxyalkoxyalkyl; and the pharmaceutically acceptable addition salts thereof.

11 Claims, No Drawings N-HYDROXYALKYL, HYDROXYALKOXYALKYL AND HYDROXYALKOXYALKOXY-ALKYL DlllPHENYL-METHYLENE-PIPERIDINES The present invention is concerned with new piperidine derivatives and with the preparation thereof. It is also concerned with compositions containing the new piperidine derivatives and with the therapeutic use thereof.

The new piperidine derivatives according to the present invention are diphenyl-methylene-piperidines of the general formula:

i Ti

of the general formula:

A n in which A has the same meaning as above with a compound of the general formula:

in which R has the same meaning as above and Z is a reactive group which is capable of reacting with the hydrogen atom on the nitrogen atom of the piperidine, Z preferably being a halogen atom;

b. submitting an alpha,alpha-diphenyl-N-R- piperidine-methanol of the general formula:

l E (1v) in which A and R have the same meanings as above, to the action of a dehydration agent, such as anhydrous hydrogen chloride in alcoholic solution.

The intermediates of general formula (II) can be prepared by the reduction of an alpha,alpha-diphenylpyridine-methanol of the general formula:

A \L A ,5?) N in which A has the same meaning as above, to give the corresponding alpha, alpha-diphenyl-piperidinemethanol of the general formula:

in which A has the same meaning as above, followed by dehydration to give the desired intermediate of general formula (II).

As far as the intermediates of general formula (IV) are concerned, they can be obtained by the condensation of an a1pha,alpha-diphenyl-piperidine-methanol of the above-given general formula (V1) with a compound of the above-given general formula (III).

The new compounds (I) according to the present invention, either in the form of the free bases or in the form of addition salts with pharmaceutically acceptable inorganic and organic acids, are very strong pharmacological agents which act upon the cardiovascular, pulmonary and central nervous systems and can also be used as antihistaminics and as anti-serotoninics.

The following Examples are given for the purpose of illustrating the present invention:

I ll (VD EXAMPLE I l-[2-(2-hydroxyethoxy)-ethyl]-4-(diphenylmethylene)-piperidine A mixture of 28 g. 4-(diphenyl-methylene)- piperidine and 25 g. 2-(2-chloroethoxy)-ethanol in 60 ml. xylene .is heated for 8 hours at 120 C. in the presence of 17.5 g. anhydrous sodium carbonate.

After cooling, the reaction mixture is filtered and the filtrate is subsequently extracted with dilute hydrochloric acid (20 ml. concentrated hydrochloric acid and ml. water). The acidic solution is separated, rendered alkaline with a concentrated solution of sodium hydroxide (about 35 ml. of 40 percent solution) and the base thus liberated is extracted with benzene. The benzene extract is washed with water and then dried over anhydrous sodium sulfate. The solution is then evaporated to dryness under reduced pressure.

The residue is dissolved in isopropanol and then converted into the hydrochloride. This melts at 221-222 C., with decomposition.

Analysis:

calc. Cl 9.48% N 3.74% found 9.58% 3.72%

The following piperidine derivatives are prepared in an analogous manner:

1 2-( 2-hydroxyethoxy )-ethyl -4-( p-chloro-diphenyl-methylene )-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 2092 1 0 C.

Analysis:

calc. total Cl l7.36% Cl 8.68% N 3.43% found: 17.38% 8.64% 3.38%

This compound is prepared from 4-(p-chlorodiphenyl-methylene)lpiperidine (m.p. 72-73 C.) which, in turn, is prepared by the dehydration of 4- (alpha-p-chlorophenyl-alpha-phenyl)-piperidinemethanol which is a known substance.

1-[2-(2-hydroxyethoxy)-ethyl]-4-(m-chloro-diphenyl-methy1ene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, has a melting point of 219-220 Analysis: C H ClNO HCl calc. total Cl 17.36% Cl 8.68% N 3.43% found 17.77% 8.88% 3.48%

This compound is prepared from 4-(m-chlorodiphenylmethylene)-piperidine (m.p. 8283 C.), which, in turn, is prepared from 4-(alpha-mchlorophenyl-alpha-phenyl)-piperidine-methano1 (m.p. 132133 C.), this being obtained by the reduction of 4-alpha-m-chlorophenyl-alpha-phenyl)- pyridine-methanol (m.p. l80-181 C.

1- 2-( 2-hydroxyethoxy )-ethyl -4-( o-chloro-diphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 243244 C.

Analysis: CHHMCINOZJ-ICI calc. total 01 17.36% Cl- 8.68% N 3.43% found: 17.60% 3.87% 3.57%

This compound is prepared from 4-(o-chlorodiphenyl-methylene)-piperidine (b.p. 132-134 C./0.001 mm.l-Ig.) which, in turn, is prepared by the dehydration of 4-(alpha-o-chlorophenyl-alpha-phenyl)-piperidine-methanol (m.p. 147-149 C.), obtained by the reduction of 4-(a1pha-o-chloropheny1-alphaphenyl)-pyridine-methanol (m.p. 202203 C.

l-[ 2-( 2-hydroxyethoxy )-ethyl -4-(m-trifluromethyldiphenyl-methylene )-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, has a melting point of 200201 C.

Analysis:

calc. Cl- 8.02% F 12.89% N 3.16%

found: 8.55% 12.80% 3.18%

This compound is prepared from 4-(m- Analysis:

calc. Cl 9.04% F 4.8% N 3.57% found: 9.02% 4.82% 3.66%

This compound is prepared from 4-(p-fluoro-diphenyl-methylene)-piperidine (m.p. 8485 C.) which, in turn, is prepared by the dehydration of 4-(alpha-pfluorophenyl-alpha-phenyl)-piperidine-methanol (m.p. -146 C.), obtained by the reduction of 4-(a1phafluorophenyl-alpha-phenyl)-pyridine-methanol (m.p. l95196 C.) which is either prepared from 4-benzoylpyridine and the bromide of p-fluorophenyl magnesium, or from 4-(p-fluorobenzoyl)-pyridine (m.p. 84-85 C.; b.p. -172 C./12 mm.Hg.) and the bromide of phenyl magnesium.

1-[ 2-( 2-hydroxyethoxy )-ethyl -4-( p-methyl-diphenyl-methylene )-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 21 32 1 4 C.

Analysis:

C H NO HG calc.: Cl 9.14% N 3.61% found 9.26% 3.56%

This compound is prepared from 4-)p-methyldiphenyl-methylene)-piperidine (m.p. 64-65 C.) which, in turn, is prepared by the dehydration of 4- (alpha-p-methylphenyl-alpha-phenyl)-piperidinemethanol (m.p. 140l41 C.), obtained by the reduction of 4-(a1pha-p-methylphenyl-alpha-phenyl)- pyridine-methanol (m.p. 195-196C.).

1-[ 2-( 2-hydroxyethoxy )-ethy1 -4-(m-methyl-diphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 2172 1 9 C.

Analysis:

calc.: Cl 9.14% N 3.61% found 9.16% 3.62%

This compound is prepared from 4-(m-methyldiphenyl-methylene)-piperidine (m.p. 7714 78 C.) which is, in turn, obtained by the dehydration of 4 (alpha-m-methylphenyl-alpha-phenyl)-piperidinemethanol (m.p. 1171 18 C.), prepared by the reduction of 4-(alpha-m-methylphenyl-alpha-phenyl)- pyridine-methanol (m.p. 178-179 C.).

1-[ 2-( 2-hydroxyethoxy )-ethyl] -3-(diphenylmethylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 1801 8 1 C.

Analysis:

calc. Cl 9.48% N 3.74% found 9.65% 3.73%

This compound is prepared from 3-(diphenylmethylene)-piperidine (m.p. 8788 C.) which, in turn, is prepared from 3-alpha,alpha-dipheny1- piperidine-methanol.

l-[ 2-( 2-hydroxyethoxy )-ethyl] -4-(4-chloro-4 fluoro-diphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystalliza tion from isopropanol, melts at 204205 C.

Analysis:

calc. total Cl 16.62% Cl 8.31% F 4.45% N 3.28% found: 16.70% 8.38% 4.60% 3.31%

This compound is prepared from 4-(4-chloro-4- fluoro-diphenyl-methylene)-piperidine (m.p. 103-l04 C.) which, in turn, is obtained by the dehydration of 4-(alpha-4-chlorophenyl-alpha-4-fiuorophenyl)- piperidine-methanol (m.p. l44l45 C.), prepared by the reduction of 4-(alpha-4-chlorophenyl-alpha-4'- fluorophenyl)-pyridine-methanol (m.p. l82l 83 C.)

l-[ 2-( 2-hydroxyethoxy )-ethyl -4-(p-trifluoromethyldiphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 202203 C.

Analysis:

CMHNFJNOTHCI calc. Cl' 8.02% F 12.89% N 3.13%

found 816% 12.90% 3.19%

This compound is prepared from 4-(p- Analysis:

calc. Cl 8.24% N3.25%

found: 8.22% 3.24%

Intermediate compounds 4-p-t-butyl-diphenyl-methylene-piperidine (m.p.

9597 C. after recrystallization from petroleum ether b.p. 40-60 C.)

4-alpha-p-t-butyl-phenyl-alpha-phenyl-piperidinemethanol (mp. 9092 C. after recrystallization from petroleum ether b.p. 4060 C.)

4-alpha-p-t-butyl-phenyl-alpha-phenyl-pyridinemethanol (m.p. l88-189 C. after recrystallization from benzene).

1- 2-( 2-hydroxyethoxy )-ethyl -4-( 3 ,4-dimethyldiphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 2l9-220 C.

Analysis:

calc. Cl 8.82% N 3.48%

found 8.90% 3.36%

Intermediate products 4-( 3 ,4-dimethyl-diphenyl-methylene )-piperidine (m.p. 96-9 8 C. after recrystallization from petroleum ether b.p. 40-60 C.)

4-alpha-(3,4-dimethylphenyl)-alpha-phenylpiperidine-methanol (mp. of the corresponding hydrochloride, after recrystallization from isopropanol, 223-224 C.)

4-alpha-(3,4-dimethylphenyl)-alpha-phenylpyridine-methanol (m.p. l6l162 C. after recrystallization from ethanol).

v 6 l-[2-( 2-hydroxyethoxy)-ethyl]-4-(p-methoxydiphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 207208 C.

Analysis:

calc. Cl" 3.77% N 3.46%

found: 8.87% 3.48%

Intermediate products 4-p-methoxy-diphenyl-methylene-piperidine (m.p. 8990 C. after recrystallization from petroleum ether b.p. 40-60 C.)

4-alpha-p-methoxyphenyl-alpha-phenyl-piperidinemethanol (which is a known substance).

1-[ 2-( 2-hydroxyethoxy )-ethyl -4-( o-methoxydiphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 205206 C.

Analysis:

calc. Cl 8.77% N 3.46%

found 8.80% 3.60%

Intermediate products 4-o-methoxy-diphenyl-methylene-piperidine (b.p. 128130 C./0.00l mm.l-lg.)

4-alpha-o-methoxyphenyl-alpha-phenyl-piperidinemethanol (m.p. l04l05 C. after recrystallization from petroleum ether b.p. 4060 C.) 4-alpha-omethoxyphenyl-alpha-phenyl-pyridine-methanol (mp. l 32133 C. after recrystallization from isopropanol.

1-) 2-[2-( 2-hydroxyethoxy)-ethoxy]-ethyl (-4- (diphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 144l 45 C.

Analysis:

calc. Cl 8.48% N 3.35% found: 8.49% 3.33%

1-) 2-[2-(2-hydroxyethoxy)-ethoxy]-ethyl l-4(pfluoro-diphenyl-methylene )-piperidine The corresponding hydrochloride, after recrystallization from ethyl-acetate, melts at l30l32 C.

Analysis:

calc.: Cl 8.l3% F 4.36% N 3.2l% found: 8.07% 4.35% 3.18%

1-2 2-[2-(2-hydroxyethoxy)-ethoxy]-ethyl l-4-(ptrifluoromethyl-diphenyl-methylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at l20-121 C.

Analysis:

C, H F .HCl calc.: Cl' 7.29% F 11.7% N 2.88% found: 7.33% 11.9% 2.87%

1- 5 2-[2-(2-hydroxyethoxy)-ethoxy]-ethyl }-4-(mtrifluoromethyl-diphenyl-methylene )-piperidine The corresponding fumarate, after recrystallization from isopropanol, melts at l35-l 36 C.

calc. found 1-12-[2-(Z-hydroxyethoxy)-ethoxy]-ethyl -4-( pchloro-diphenyl-rnethylene )-piperidine The corresponding fumarate, after recrystallization from isopropanol, melts at lO2-103 C.

Analysis:

calc. Cl 6.66% N 2.63% found 6.30% 2.59%

l-( 2,3-dihydroxypropyl)-4-(diphenyl-methylene)- piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 21 12 1 2 C.

Analysis:

calc.: Cl 9.85% N 3.89% found 9.74%% 3.86%

1-(2-hydroxyethy1)-4-(diphenyl-methylene)- piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 229230 C.

Analysis:

calc. C1 10.74% N 4.24% found 10.26% 4.26%

1-(2-hydroxyethyl)-4-(p-chloro-diphenylmethy1ene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at l85-186 C.

Analysis:

calc. Cl 9.73% total C1 19.46% N 3.84% found: 992% 19.83% 3.85%

l -(2-hydroxyethyl)-4-(p-f1uoro-diphenylmethylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 21 72 1 8 C.

Analysis:

calc C1 10.19% F 5.46% N 4.27% found 10.48% 5.42% 3.99%

1-(2-hydroxyethy1)-4-(o-methoxy-diphenylmethylene )-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 190-l 9 1 C.

Analysis:

calc.: Cl 9.85% N 3.89% found 10.20% 3.80%

1-( 2-hydroxyethyl )-4-( m-rnethyl-diphenylmethylene)-piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 201202 C.

Analysis:

calc.: C1 10.31% N 4.07% found 10.34% 4.02%

1-( 3-hydroxypropyl )-4-( diphenyl-methylene piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 190-l 91 C.

Analysis:

calc. C1 10.31% N 4.07% found: 10.48% 4.01%

1-(4-hydroxybutyl)-4-(diphenyl-methylene)- piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 185-l 86 C.

Analysis:

calc. 1 Cl" 9.90% N 3.91% found: 9.86% 3.91%

l (2-hydroxyethy1)-3-(diphenyl-methylene)- piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at 164-1 65 c.

Analysis: CZDHHNOHCI calc. C1 10.74% N 4.24% found 11.1% 4.22%

1-( 3-hydroxypropyl )-3-(diphenyl-methylene piperidine The corresponding hydrochloride, after recrystallization from isopropanol, melts at l76l 77 C.

Analysis: c,,H ,No.Hc1 calc. 1 01- 10.31% N 4.07% found 10.26% 4.02%

1-1 2-[2-(2-hydroxyethoxy)-ethoxy]-ethy1 {-4-(4- chloro-diphenyl-methylene)-piperidine The corresponding fumarate, after recrystallization from isopropanol, melts at 102103 C.

Analysis: C,,H,,,C1N0,.C,H,0, calc.: C16.66% N 2.63% found: 552% 2.59%

1- 2-[2-( 2-hydroxyethoxy)-ethoxy]-ethyl ;-4-( 3- trifluoromethyl-diphenyl-methylene )-piperidine The corresponding fumarate, after recrystallization from isopropanol, melts at 136 C.

Analysis:

calc. F 10.07% N 2.47%

found: 10.14% 2.47%

EXAMPLE 2 A solution of g. l-[2-(2-hydroxyethoxy)-ethyl]-4- (alpha,alpha-diphenyl)-piperidine-methanol hydrochloride in 500 ml. ethanol is saturated in the cold with gaseous hydrogen chloride. After leaving to stand overnight, the reaction mixture is boiled under reflux for 20 minutes.

The reaction mixture is then evaporated to dryness and the residue recrystallized from isopropanol. The product obtained has a melting point of 22l222 C.

Analysis:

C H NO HCI calc. Cl 9.48% N 3.74% found 9.48% 3.78%

The l 2-(2-hydroxyethoxy)-ethyl]-4-(alpha,alphadiphenyl)-piperidine-methanol, which is here used as starting material, is prepared from 4-(alpha,alphadiphenyl)-piperidine-methanol and 2-(2-chloroethoxy)-ethanol in the manner described in Example 1 for the condensation of the same chlorhydrin with 4- (diphenyl-methylene)-piperidine. After recrystallization from isopropanol, the corresponding hydrochloride has a melting point of 229230 C.

The following compounds have been prepared by the same method:

l- 2-( Z-hydroxyethoxy )-ethyl] -3-(diphenylmethylene)-piperidine (The preparation of this compound by the first method has already been described in Example 1).

Four g. l- 2-( 2-hydroxyethoxy )-ethyl -3- alpha,alpha-diphenyl-piperidine-methanol hdyrochloride are dissolved in 100 ml. ethanol. The solution is saturated in the cold with gaseous hydrogen chloride, then it is boiled under reflux for about 4 hours. The residue after evaporation under vacuum on the water-bath is crystallized from isopropanol.

The corresponding hydrochloride of the obtained product melts at l80l81 C. (no depression of m.p. when this compound is mixed with the one obtained by the first method).

Analysis: C H,-,NO .HCI calc. Cl 9.48% N 3.74% found 10.09% 3.77%

The l-[2-(2-hydroxyethoxy)-ethyl]-3-alpha,alpha- Analysis:

calc.: Cl 9.04% N 3.57% found 9.11% 3.49%

1-( 2-hydroxyethyl )-2-( diphenyl-methylene piperidine.

A solution of g. l-(2-hydroxyethyl)-2- alpha,alpha-diphenyl-piperidine-methanol hydrobromide in 100 ml. concentrated hydrobromic acid is heated for 4 hours at C. The reaction mixture is cooled in an ice-salt mixture and the supernatant solution is decanted. The residue is twice evaporated to dryness under vacuum on the water-bath, while adding each time 50 ml. isopropanol. The residue is finally crystallized from acetone. The corresponding hydrobromide of the obtained product melts at 283284 C.

Analysis: c H NQl-lBr calc. Br 21.34% N 3.74% found 21.92% 2.70%

The 1-(2-hydroxyethyl)-2-alpha,alpha-diphenyl- Analysis: C H, NO,.HBr calc.: Br 20.37% N 3.57% found: l9.76% 3.56%

EXAMPLE 3 Pharmacologic Tests In these tests, use was made of the following compounds according to the invention:

compound I: 1- 2-( 2-hydroxyethoxy )-ethyl -4- (diphenyl-methylene)-piperidine.

compound II: l-[2-(2-hydroxyethoxy)-ethyl]-4-(pchloro-diphenyl-methylene)-piperidine.

compound III: l-[ 2-( 2-hydroxyethoxy )-ethyl -4-( mchloro-diphenyl-methylene)-piperidine.

compound IV: 1-[2-(2-hydroxyethoxy)-ethyl]-4-(ochloro-diphenyl-methylene)-piperidine.

compound V: l-[2-(2-hydroxyethoxy)-ethyl]-4-(pfluoro-diphenyl-methylene)-piperidine.

compound VI: l-[2-(2-hydroxyethoxy(-ethyl]-4-(pmethyl-diphenyl-methylene)-piperidine.

compound VII: l[2-( 2-hydroxyethoxy)-ethyl]-4-(mmethyl-diphenyl-methylene)-piperidine.

compound VIII: l-[2-(2-hydroxyethoxy)-ethyl]-4- (p-methoxy-diphenyl-methylene)-piperidine.

compound IX: l-[2-(Z-hydroxyethoxy)-ethyl]4-(omethoxy-diphenyl-methylene)-piperidine.

compound X: l-E2-[2-(2-hydroxethoxy)-ethoxy]- ethyl l-4-(diphenyl-methylene )-piperidine.

compound XI: l-E2-[2-(2-hydroxyethoxy)-ethoxy]- ethyl l-4-(p-fluoro-diphenyl-methylene)- piperidine.

compound XII: l-(2-hydroxyethyl)-4-(diphenylmethylene)-piperidine.

Compound XIII: l-(2-hydroxyethyl-4-(p-fluorodiphenyl-methylene)-piperidine.

compound XIV: 1-[2-(2-hydroxyethoxy)-ethyl]-4- (m-trifluoromethyl-diphenyl-methylene)- piperidine.

compound XV: l-[2-( 2-hydroxyethoxy)-ethyl]-4-(pchloro-p'-fluoro-diphenyl-methylene)-piperidine.

Bronchodilating effects 1. In bronchitic dogs Method: The dogs are rendered bronchitic by exposure to S (cfr. J. LULLING, l. PRIGNOT, P. LIEVENS, Arch.Pharmak.u.exp.Path.26l, (l968),l25). In these animals, the viscous resistance (R) of the respiratory tract is particularly high.

Results: A very distinct decrease of the resistance (R), exceeding 50 percent, is obtained after administration of compound I (2 mgJkg. intravenously) or compound X (0.1 mg./kg. intravenously or I mg./kg. per 0s).

A less important decrease (30 percent) was found after administration of compounds XI and XII (0.32 mg./kg. intravenously).

A similar effect is obtained after intravenous administration of theophylline at the dose of 4 mg./kg.

2. In guinea-pigs Method: A variant of the Konzett-Rossler method (cfr. H. KONZETT and R. ROSSLER, Arch.expo.Path.Parmakol,l95,(l940),7174) is applied. The anesthetized and curarized guinea-pig is subjected to artificial respiration. The endotracheal pressure is recorded. Repeated bronchial spasms are induced by successive intravenous injections of acetycholine, histamine or serotonine. The 50 percent efficaceous dose (ED 50) that inhibits these spasms is calculated.

Results: The ED 50 towards the various induced bronchospasms are given in the following Table.

These substances prove to have a moderate antibronchoconstricting effect towards acetylcholine and considerable antagonistic effects towards histaminic and particularly serotoninic bronchospasms.

ED 50 (in mg./kg.)

Antihistaminic activity The antihistaminic activity of these substances has been studied in guinea-pigs by the BOVET and STAUB method (C.R.Soc.Biol. l 24,( l 937),547) as modified by S. LEVIS et a1. (Arch.Intern.Pharmacod.l09,(l957),1 28). This test consists in determining the number of toxic doses of intravenously injected histamine that are neutralized by the previous administration of an antihistaminic agent. The extent and the duration of this activity are evaluated.

The substances to be tested are administered intravenously (2.5 mg./kg.) or orally (2.5 mg./kg.,per catheter).

In the control animals, the minimum dose of intravenously administered histamine hydrochloride that kills 100 percent of guinea-pigs, of 300 to 400 g. body weight, varies between 0.4 and 0.5 mg./kg.

The results are given in the following Table:

Toxic doses of histamine neutralized after 1 hour after 4 hours Compound intravenously orally intravenously orally 1 600 11 600 600 111 1200 1000 V 1200 1000 X 800 1000 X1 1000 XV 600 600 400 600 The activity of compound XV, after 24 hours, is still 400 (when administered intravenously) and 600 (when administered orally).

Circulatory effects in vivo Method: In anesthetized dogs, subjected to artificial respiration, the hemodynamic effects are studied under the experimental conditions described by WELLENS and WAUTERS (Arch.int.Pharrnacodyn.171, (1968),246250). The cardiac, musculo-cutaneous and cerebral outputs are measured by means of periarterial probes placed respectively around the aorta and the femoral and vertebral arteries.

Results:

The musculo-cutaneous peripheric output is con siderably stimulated by most of the tested compounds. A significant increase (more than 20 percent, during more than 20 minutes) is observed after intravenous administration of l mg./kg. of compounds I and V, and of 2 mg./kg. of compounds II, VI, X, XI, X11 and XIV. In certain cases, the increase in femoral output is very important (50 to percent) and may last more than 1 or 2 hours. Such effects are observed after administration of compound V 0.1 to 2 mg./kg. intravenously or 2 to 10 mg./kg. intraduodenally.

Because of its physiologic regulation, the cerebral output cannot be subjected to variations that are as important as those observed in the musculo-cutaneous circulation.

A moderate but significant increase in cerebral output is produced by several of the tested compounds, particularly by compound V (l mgJkg. intravenously) and compound XII (2 mg/kg. intravenously).

The vasodilating effects on femoral and cerebral circulation are relatively specific, in the sense that they are accompanied by a much lesser or even nil stimulation of the cardiac output.

In the same experimental conditions, theophylline does not appreciably increase the femoral output; on the other hand, it produces a high increase of cerebral output, but only at the intravenous dose of 20 mg./kg. This latter effect is accompanied by an important acceleration of cardiac rhythm.

Conclusion:

The tested compounds according to the invention have a benefic effect on blood supply in the musculocutaneous and cerebral regions.

Coronarodilating effect as measured by the Langendorff method Method: the isolated heart of rabbit is fibrillated by electric stimulation. The coronary region is perfused by cannulation of the aorta. The perfusion pressure is constant and the output of the perfusion liquid (tyrode) is measured.

Results: These are given in the following Table:

Number of animals Increase of output in Compound ll 5 113 12 20 I45 12 III 5 103 12 IV 5 81 12 V 1 24 12 2 55 12 VI 5 119 9 VII 5 I21 9 20 I72 12 Theophylline 20 31 12 5O 39 12 Conclusion: In this test, the various compounds have a very important coronarodilating effect, which by .far outpasses that of theophylline.

Effects on the central nervous system The activity of the compounds according to the invention on the central nervous system has been determined by means of the following tests: Potentiation of pentobarbital: P. JANSSEN, C. VAN DE WESTERINGH, A. JAGUENAU, P. DEMOEN, B. HERMANS, G. VAN DAELE, K. SCHELLEKENS, C. VAN DER EYCKEN, C. NIEMEGEERS, J.Med.Pharm.Chem. l 1959), 281-297. Rotating rod: N.W. DUNHAM, J .Am.Pharm.Assoc.46,( 1957),208-209. Behavior (exciting or sedative): S. IRWIN, Gordon Research Conference on Medicinal Chemistry, Aug. 1959), 3-7, Colby Junior College, New London). Electro-encephalogram (abbreviated EEG): S. GIUR- GEA and MOEYERSOONS, Med.Exp. 8,( I963 ),66.

The results obtained by these tests are summarized in the following Table:

T.S. MIYA,

M mouse; 0 oral administration; R rat; P parenteral administration; the numerical values are expressed in mgjkg. animal body weight; the smaller the numeric value, the more the tested compound proves to be active.

Whether free bases or salts or inorganic or organic pharmaceutically acceptable acids, the compounds according to the invention may be administered orally, rectally or parenterally at unit doses of 10 to 60 mg. and, in accordance with the mode of administration, in association with adjuvants and solvents commonly used in pharmacy.

I claim: 1. A diphenyl-methylene-piperidine of the formula:

A R wherein A is a member selected from the group consisting of hydrogen, halogen, cyano, halomethyl, alkyl and alkoxy, and

R is a member selected from the group consisting of hydroxyalkyl, hydroxyalkoxyalkyl and hydroxyalkoxyalkoxyalkyl, each alkyl and alkoxy containing one to four carbon atoms;

or an addition salt thereof with pharrnaceutically acceptable acids.

2. 1- 2-( 2-hydroxyethoxy )-ethyl -4-( p-fluorodiphenyl-methylene)-piperidine.

3. l-l 2-[ 2-(2-hydroxyethoxy)-ethoxy]-ethyl 1-4- (diphenyl-methylene)-piperidine.

4. 1-[2-(2-hydroxyethoxy)-ethyl]-4-(p-chlorodiphenyl-methylene)-piperidine.

5 1-[2-(2-hydroxyethexy)-ethyl]-4-(diphenylmethylene)-piperidine.

6. l- 2-[2-(2-hydroxyethoxy)-ethexy]-ethyl -4-(pfluoro-diphenyl-methylene)-piperidine.

7. l-[ 2-( 2-hydroxyethoxy)-ethyl ]-4-( p-methoxydiphenyl-methylene)-piperidine.

8. l-[ 2-( 2-hydroxyethoxy )-ethyl -4-p-chloro-p fluoro-diphenyl-methylene)-piperidine.

l-[ 2-( 2-hydroxyethoxy )-ethyl -4-( mtrifluoromethyl-diphenyl-methylene)-piperidine.

10. I 1-( 2-hydroxyethyl )-4-( diphenyl-methylene piperidine.

1 l l-( 2-hydroxyethyl )-4-(p-fluoro-diphenylmethylene)-piperidine. 

2. 1-(2-(2-hydroxyethoxy)-ethyl)-4-(p-fluoro-diphenyl-methylene)-piperidine.
 3. 1-(2-(2-(2-hydroxyethoxy)-ethoxy)-ethyl)-4-(diphenyl-methylene)-piperidine.
 4. 1-(2-(2-hydroxyethoxy)-ethyl)-4-(p-chloro-diphenyl-methylene)-piperidine.
 5. 1-(2-(2-hydroxyethoxy)-ethyl)-4-(diphenyl-methylene)-piperidine.
 6. 1-(2-(2-(2-hydroxyethoxy)-ethoxy)-ethyl)-4-(p-fluoro-diphenyl-methylene) -piperidine.
 7. 1-(2-(2-hydroxyethoxy)-ethyl)-4-(p-methoxy-diphenyl-methylene)-piperidine.
 8. 1-(2-(2-hydroxyethoxy)-ethyl)-4-p-chloro-p''-fluoro-diphenyl-methylene) -piperidine.
 9. 1-(2-(2-hydroxyethoxy)-ethyl)-4-(m-trifluoromethyl-diphenyl-methylene) -piperidine.
 10. 1-(2-hydroxyethyl)-4-(diphenyl-methylene)-piperidine.
 11. 1-(2-hydroxyethyl)-4-(p-fluoro-diphenyl-methylene)-piperidine. 